10-Q: Theravance Biopharma Swings to Profit on TRELEGY Royalty Sale

Theravance Biopharma reported a significant net income for the nine months ended September 30, 2025, driven by a $75.1 million gain from the sale of its remaining TRELEGY royalties to GSK, while advancing its ampreloxetine Phase 3 study.

Summary

• Achieved a net income of $44.9 million for the nine months ended September 30, 2025, a substantial improvement from a $40.9 million net loss in the prior year period.
• This profitability was primarily driven by a one-time $75.1 million net gain from the sale of remaining TRELEGY royalties to GSK in May 2025.
• Total revenues increased by 35% to $61.6 million for the nine months ended September 30, 2025, including a $7.5 million licensing revenue from YUPELRI's China NMPA approval.
• YUPELRI net sales (Theravance Biopharma's implied 35% share) grew 14% year-over-year to $68.6 million for the nine months ended September 30, 2025.
• Cash, cash equivalents, and marketable securities significantly increased to $332.7 million as of September 30, 2025, from $88.3 million at December 31, 2024.
• The Phase 3 CYPRESS study for ampreloxetine completed patient enrollment in late-August 2025, with top-line data expected in Q1 2026.
• Settled patent infringement litigation with seven generic companies for YUPELRI, granting licenses for US launch on or after April 23, 2039, while litigation against Mankind Pharma Ltd. remains pending.

Sentiment

Score: 8

Explanation: The company demonstrated a strong financial turnaround, primarily driven by a significant one-time gain from the sale of TRELEGY royalties, leading to substantial net income and improved liquidity. Progress in the ampreloxetine Phase 3 study and YUPELRI's international approval are positive operational developments. While operational profitability (excluding the one-time gain) is still a focus, the strengthened cash position and strategic asset management are highly favorable. The ongoing patent litigation for YUPELRI and the competitive landscape are noted risks, but the overall financial health and pipeline progress are positive.

Positives

• Achieved net income of $44.9 million for the nine months ended September 30, 2025, a significant turnaround from a $40.9 million net loss in the prior year.
• Realized a $75.1 million net gain from the sale of remaining TRELEGY royalties to GSK, bolstering the financial position.
• Cash, cash equivalents, and marketable securities increased substantially to $332.7 million, providing strong liquidity.
• YUPELRI received regulatory approval from China's NMPA in June 2025, triggering a $7.5 million milestone payment.
• YUPELRI's implied 35% share of net sales increased by 14% year-over-year for the nine months ended September 30, 2025, driven by customer demand growth and improved net pricing.
• The Phase 3 CYPRESS study for ampreloxetine completed patient enrollment, moving closer to potential top-line data in Q1 2026.
• Ampreloxetine received Orphan Drug Designation from the FDA, which could provide market exclusivity and other benefits.
• Settled patent litigation with seven generic companies for YUPELRI, securing market exclusivity until at least April 23, 2039, for those parties.
• Expects cash, cash equivalents, and marketable securities to be sufficient to fund operations for at least the next twelve months.

Negatives

• Incurred a net loss of $6.5 million from operations for the three months ended September 30, 2025.
• R&D expenses increased by $1.9 million for the nine months ended September 30, 2025, primarily due to ampreloxetine development and regulatory activities.
• SG&A expenses increased by $4.5 million for the nine months ended September 30, 2025, partly due to one-time legal costs and pre-launch activities for ampreloxetine.
• Litigation against one generic company (Mankind Pharma Ltd.) regarding YUPELRI patents remains pending.
• The company's profitability for the nine months ended September 30, 2025, was largely driven by a one-time gain, indicating that operational profitability is not yet sustained.

Risks

• May never achieve or sustain profitability from operations.
• YUPELRI's acceptance by physicians, patients, third-party payors, or the medical community may not continue to grow, impacting revenues.
• Risks associated with co-promoting YUPELRI in the US with Viatris, including costs, ability to retain sales personnel, and competitive disadvantage.
• Delays or adverse results in clinical studies for product candidates (e.g., ampreloxetine) or regulatory obstacles could harm the business.
• Product candidates may not be approved by regulatory authorities, preventing commercialization.
• Partners may not satisfy obligations or may terminate partnerships, affecting development and commercialization.
• Ongoing drug development efforts might not generate additional approvable drugs, with past failures (izencitinib, SEQUOIA study for ampreloxetine) as examples.
• The strategic review process may not result in additional transactions or could adversely affect the business and shareholder value.
• Substantial competition from companies with more resources and experience, potentially leading to others commercializing products more successfully.
• Reliance on single sources of supply for product candidates and YUPELRI, with potential harm if manufacturers fail to satisfy demand.
• Extensive and ongoing regulation by the FDA and other authorities, with failure to comply leading to penalties or adverse impact on commercialization.
• Competition from companies seeking to market generic versions of approved products like YUPELRI, potentially challenging patents.
• Inability to enter into future collaboration arrangements or unsuccessful collaborations could hinder development and commercialization.
• Dependence on third parties for non-clinical and clinical studies, with risks of delays or non-approval if they fail to comply with regulations.
• Adverse developments or perceived adverse developments with respect to TRELEGY could impact Milestone Payments from Royalty Pharma.
• Loss of key management, sales, clinical development, or scientific personnel, or failure to attract and retain key employees.
• Significant disruptions of information technology systems or security breaches could harm business operations, reputation, and financial results.
• Global economic, political, and social conditions (e.g., war, inflation, government shutdowns, trade policies) may harm business, increase costs, and negatively affect stock price.
• Facility located near earthquake fault zones, vulnerable to damage from natural disasters or other catastrophic events.
• Insufficient capital could lead to curtailment of operations, relinquishing rights, or further workforce reductions.
• Future financing through debt or equity issuance may dilute shareholders or impose restrictive covenants.
• Potential treatment as a US corporation for US federal income tax purposes under Section 7874 of the Code.
• Future tax reform, including changes in tax rates and imposition of new taxes, could impact results.
• Taxing authorities may challenge the company's structure and transfer pricing arrangements.
• Risk of being classified as a Passive Foreign Investment Company (PFIC) for US federal income tax purposes (though not expected for foreseeable future).
• Inability to maintain effective internal controls could adversely affect business, financial position, and results.
• Inadequate protection of intellectual property (patents, trade secrets) could erode competitive position.
• Litigation to protect intellectual property or third-party claims of infringement could divert resources and delay development.
• Product liability and other lawsuits could divert resources, result in substantial liabilities, and reduce commercial potential.
• FDA's shift toward radical transparency (e.g., releasing complete response letters) could have an adverse impact on business and commercial prospects.
• Failure to comply with data protection laws and regulations (e.g., CCPA, GDPR) could lead to enforcement actions, litigation, and adverse publicity.
• Changes in healthcare law and regulations, including government restrictions on pricing and reimbursement, may negatively impact the company.
• Uncertainty regarding coverage and reimbursement status of new or current products could limit marketability and revenue generation.
• Relationships with customers and third-party payors are subject to anti-kickback, fraud and abuse, and transparency laws, exposing the company to sanctions.
• Business and operations involving hazardous and biological materials may result in environmental, health, and safety liabilities.
• Market price for shares has and may continue to fluctuate widely, resulting in substantial losses.
• Activist shareholders could negatively impact business and cause disruptions.
• Concentration of ownership limits ability to influence corporate matters.
• Certain provisions in constitutional documents may discourage acquisition by a third party.
• Shareholders may face difficulties in protecting their interests because the company is incorporated under Cayman Islands law.
• Uncertainty as to shareholders' ability to enforce certain foreign civil liabilities in the Cayman Islands.
• If securities or industry analysts cease coverage or publish inaccurate/unfavorable research, stock price and trading volume could decline.
• Capital appreciation of ordinary shares may be the sole source of gain for the foreseeable future, as no cash dividends have been paid.
• As a smaller reporting company, reduced reporting and disclosure requirements could make shares less attractive to investors.

Future Outlook

The company expects top-line data from its Phase 3 CYPRESS study for ampreloxetine to be available in the first quarter of 2026. It anticipates a more stable pricing environment and continued YUPELRI demand growth in 2025 and beyond, though improvements to net pricing are expected to moderate. The Strategic Review Committee will continue to evaluate a range of alternatives to further enhance shareholder value, with no assurance of additional transactions. The company believes its current cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next twelve months.

Management Comments

• "Our focus is to deliver medicines that make a difference in people's lives."
• "We expect our cash, cash equivalents, and marketable securities will be sufficient to fund our operations for at least the next twelve months from the issuance date of these condensed consolidated financial statements based on current operating plans and financial forecasts."
• "We view customer demand as the primary driver for the brand and believe improvements to net pricing will likely moderate in the future."
• "We remain focused on disciplined capital allocation and returning excess cash to shareholders, and the Committee will continue to evaluate a range of alternatives to further enhance shareholder value, though there can be no assurance that additional transactions will occur."

Industry Context

The biopharmaceutical industry continues to see strategic asset divestitures and collaborations as companies optimize portfolios and seek to unlock shareholder value. Theravance Biopharma's sale of TRELEGY royalties aligns with this trend, providing significant non-dilutive capital. The competitive landscape for COPD treatments, where YUPELRI operates, is evolving with new entrants like Verona Pharma's ensifentrine and Sanofi/Regeneron's Dupixent, intensifying pressure on existing therapies. The development of ampreloxetine for nOH in MSA patients targets an orphan disease, a common strategy for biopharma companies seeking to address unmet medical needs and potentially benefit from expedited regulatory pathways and market exclusivity.

Comparison to Industry Standards

• YUPELRI competes with short-acting nebulized bronchodilators dosed three to four times per day, offering a once-daily advantage.
• New competitors in the COPD market include Verona Pharma plc's ensifentrine (launched June 2024) and Sanofi and Regeneron Pharmaceutical, Inc.'s Dupixent (recently approved for moderate-to-severe COPD with Type 2 inflammation).
• Ampreloxetine, if approved, would enter a market where generic droxidopa is the sole approved product for nOH patients and midodrine is approved for OH, positioning it as a potential first-in-class therapy for MSA patients with symptomatic nOH.
• TRELEGY global net sales for the nine months ended September 30, 2025, were $2.92 billion, representing 13% year-over-year growth, with consensus estimates projecting peak sales of approximately $4.0 billion in 2026. This indicates strong market performance for the divested asset.

Corporate Governance

Legal Proceedings

• Patent infringement suits filed in February 2023 against Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Inc.; Mankind Pharma Ltd.; Orbicular Pharmaceutical Technologies Private Limited; and Teva Pharmaceuticals, Inc. for generic versions of YUPELRI.
• Suits in Delaware and North Carolina dismissed, consolidated in New Jersey.
• Amended complaint in December 2023 to include non-Orange Book patents.
• Additional suits filed in August 2023, January 2024, August 2024, and May 2025 based on newly granted YUPELRI patents.
• Suit filed in June 2024 against Qilu Pharmaceuticals Co., Ltd. for generic YUPELRI.
• As of October 31, 2025, settled litigation with Accord, Cipla, Eugia, Lupin, Orbicular, Qilu, and Teva, granting royalty-free licenses for US launch on or after April 23, 2039.
• Patent litigation against Mankind Pharma Ltd. remains pending.
• FDA stay of approval for generic ANDAs through May 2026.

Stakeholder Impact

• Shareholders: Significant increase in net income and cash position due to the TRELEGY royalty sale, potentially enhancing shareholder value. Ongoing strategic review aims to unlock further value. Patent settlements provide long-term clarity on YUPELRI's market exclusivity.
• Employees: Continued investment in R&D and commercialization activities for ampreloxetine and YUPELRI, but also past headcount reductions and intense competition for skilled personnel in the Bay Area.
• Customers/Patients: Continued availability and commercialization of YUPELRI for COPD patients, with new approval in China. Ampreloxetine's progress offers hope for MSA patients with nOH.
• Partners (Viatris, GSK, Royalty Pharma): Continued collaboration with Viatris for YUPELRI, and successful monetization of TRELEGY royalties with GSK and Royalty Pharma.
• Creditors: No long-term debt and a strong cash position reduce credit risk.

Next Steps

• Expect top-line data from the Ampreloxetine Phase 3 CYPRESS study in the first quarter of 2026.
• Continue to pursue potential Milestone Payments from Royalty Pharma for TRELEGY global net sales in 2025 and 2026 (up to $150.0 million remaining).
• The Strategic Review Committee will continue to evaluate a range of alternatives to further enhance shareholder value.
• Continue to co-promote YUPELRI in the US with Viatris and support its commercialization in China.
• Ongoing patent litigation against Mankind Pharma Ltd. for YUPELRI.

Key Dates

Recommendation

The company has significantly improved its financial position with a substantial net income and increased cash reserves, primarily driven by the strategic sale of TRELEGY royalties. This provides a strong liquidity runway for ongoing operations and pipeline development. Positive developments include YUPELRI's China approval and the advancement of the ampreloxetine Phase 3 study, with top-line data expected in Q1 2026. However, the core operational profitability (excluding the one-time gain) is still developing, and the company faces ongoing R&D and SG&A expenses. The YUPELRI patent litigation, while largely settled, still has one pending case, and the competitive landscape for both YUPELRI and ampreloxetine is intense. The stock price has historically been volatile, and while the current financial strength is positive, the future largely hinges on the successful development and commercialization of ampreloxetine and sustained growth of YUPELRI, which are subject to inherent biopharmaceutical risks. A 'hold' recommendation reflects the improved financial stability and pipeline potential, balanced against the need for sustained operational profitability and successful clinical outcomes.

Keywords

Biopharmaceutical, COPD, YUPELRI, Ampreloxetine, Neurogenic Orthostatic Hypotension, Multiple System Atrophy, SEC Filing, 10-Q, Financial Results, Drug Development, Clinical Trials, Patent Litigation, Royalty Sale, TRELEGY, Viatris, GSK, Orphan Drug Designation, Capital Resources, Shareholder Value, Strategic Review